5.jpg)
QT Vascular Ltd., a global company engaged in the design, assembly and distribution of advanced therapeutic solutions for the minimally invasive treatment of vascular disease, has signed a definitive agreement with Medtronic for the worldwide distribution of its Chocolate PTA catheter for a period of five years and automatically renewable for two additional one-year periods. The parties continue to negotiate other aspects of their commercial relationship.
Chocolate represents a breakthrough in PTA design. Its unique nitinol constraining structure is designed to provide atraumatic dilatation in the treatment of blocked arteries. The Chocolate BAR1 post-market registry of 490 patients showed that use of Chocolate PTA resulted in low rates of dissections and bailout stenting. Chocolate PTA may be used as a stand-alone treatment or adjunctive treatment for stenosis in vessels above and below the knee. It is approved for use in the United States, Europe, Australia, Turkey, Singapore and Hong Kong.
"We are honoured to partner with Medtronic, the world's leading medical device company. Through our direct and indirect sales channels, the adoption of Chocolate PTA has expanded steadily over the past several years. It is now available in hundreds of hospitals worldwide, and we expect Medtronic's global commercial capabilities will further expand the reach of this device both inside and outside the United States," stated Eitan Konstantino, PhD, chief executive officer of QT Vascular, "Our other products continue to attract interest and we are evaluating additional M&A transactions and strategic options to further enhance value."
Current sales of Chocolate PTA in the United States are conducted through the direct sales force of the Company's wholly-owned subsidiary, TriReme Medical LLC, and a distribution partner. Outside the United States, sales are conducted via country-specific distribution partners. Under the new distribution agreement with Medtronic, transition of the Chocolate PTA business will occur on a country-by-country basis over the coming months starting with the United States.
The agreement with Medtronic is not expected to have any material effect on the earnings/loss per share and net tangible assets/liabilities per share of the group for the financial year ending 31 December 2017.
In addition to the agreement and further to the company's update announcement dated 26 January 2017 the parties continue to negotiate other aspects of their commercial relationship. The Company plans to focus on its drug coated Chocolate programme, which demonstrated positive clinical data to date and have full IDE approval from the United States Food and Drug Administration.
Qt vascular signs pact with medtroni, worldwide distribution, chocolate pta catheter
6.png)
